Search Results 61-70 of 23121 for B cell lymphomas
Clinical Trials · MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL).
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax ...
Lymphomas are cancers that affect white blood cells in the lymphatic system — a network of organs, glands, vessels and clusters of cells called lymph nodes. B- ...
Giving rituximab together with romidepsin and lenalidomide may be a better treatment for B-cell non-Hodgkin lymphoma. Participation eligibility. Participant ...
N. Nora Bennani, M.D.. Internist; Oncologist; Hematologist. Rochester, MN. Areas of focus: CAR-T cell therapy, B- ...
The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.
Patients with large B-cell lymphoma who do not respond to an anthracycline-based front-line chemoimmunotherapy or who show evidence of relapse within 12 months ...
Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma.
T-cell/histiocyte-rich large B cell lymphoma. Large B-cell lymphoma with ... FDG-nonavid lymphomas: Measurable disease with CT (or MRI) scan with ...
AXL was identified as a potential therapeutic target in chronic lymphocytic leukemia (CLL). TP 0903 was shown to induce apoptosis in CLL B-cells taken directly ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.